Zimmer Biomet Holdings, Inc (ZBH) Stock AnalysisZBHZimmer Biomet Holdings, Inc

Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Zimmer Biomet Holdings Inc is a good buy right now due to its recent strong performance, including a Q2 non-GAAP EPS of $2.07, which exceeded expectations by $0.06, and a revenue of $2.18 billion, reflecting a 4.8% year-over-year increase. The forward P/E ratio of 11.93 suggests the stock is undervalued compared to its earnings potential. However, a key risk is the recent 1-year change of -3.90%, indicating some volatility in the stock's performance over the past year.

28 analysts cover ZBH: 18 rate it Buy, 9 Hold and 1 Sell. The average price target is 100.47.